The 2026 Nobel medicine prize: what to know about optogenetics

The research began with a question about a single-celled alga: how does it respond to light? Hegemann and his colleagues identified light-sensitive proteins called channelrhodopsins. Deisseroth later adapted the protein for experiments involving nerve cells, helping turn a discovery about algae into a neuroscience tool.

In 2005, Deisseroth published work showing that blue light could trigger nerve signals in cells carrying the channelrhodopsin gene. Two years later, he demonstrated the approach in the brains of living mice. Those steps helped researchers study targeted nerve-cell activity in a living brain.

Optogenetics enables researchers to test cause-and-effect relationships between neural activity, brain function and behavior. Optogenetics offers a way to manipulate selected cells and investigate that relationship. Researchers now use it to study circuits connected with memory, feelings and behavior, Euronews reported.

That ability to test specific circuits is the central advance recognized by the Nobel Assembly. It allows researchers to ask more precise questions about how brain activity relates to behavior and disease, without suggesting that the research has already produced a clinical solution.

What conditions are researchers investigating?

Studies using optogenetics have examined neural circuits relevant to neurological and psychiatric conditions, including depression, schizophrenia, anxiety, Alzheimer’s disease, Parkinson’s disease and epilepsy. Those are areas of research, not conditions the technique is established to treat.

That distinction matters to people living with those conditions and families seeking new options. The Nobel recognizes discoveries that enable experiments on the brain; it does not show that optogenetics can cure, prevent or treat the diseases being studied.

Researchers are also exploring the method in efforts to restore sight for people with visual impairment. Euronews reported partial vision in one blind patient using light-emitting goggles as part of this work. That reported result does not establish how well the approach works for other people, how long any benefit lasts or whether it will become routine care.

For people with vision loss, the difference between a research result and an available therapy is consequential. The reports do not resolve questions about safety, durability or access to any future treatment, and they give no timeline for wider availability.

The same caution applies to research on neurological and psychiatric conditions. A method that helps scientists investigate how cells affect brain activity may improve understanding, but that alone does not tell patients whether a treatment will follow, who could receive it or when.

What does the Nobel Committee say the discovery makes possible?

The award highlights a shift in what researchers can test: by controlling selected cells with light, they can investigate how activity in particular circuits shapes brain function. Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said optogenetics offers new possibilities for mapping the brain.

Mapping and treating are different goals. The method gives researchers a way to probe brain circuits; current research includes work on disease and attempts to restore sight, but the reporting does not establish an approved, routine therapy arising from the discoveries.

The Nobel prize amount is 12 million Swedish kronor, which TIME reported as approximately $1.2 million. Coverage does not specify how that sum will be divided among Deisseroth, Hegemann and Nagel.

What comes next for the Nobel announcements and optogenetics?

The medicine prize was the first Nobel announcement of the week. The physics award is scheduled for Oct. 6, chemistry for Oct. 7, literature for Oct. 8 and the Peace Prize for Oct. 9; the economics prize is scheduled for Oct. 12, TIME reported. Those are announcement dates, not results.

For optogenetics, a central open question is whether research applications will lead to treatments that are safe, durable and accessible. The available reporting gives no timeline for whether or when the technique could become an approved, routine treatment. The award recognizes a scientific tool; what it may eventually mean for people with vision loss or brain disorders remains to be established.